NYSE : TAK
Takeda Pharmaceutical Company Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Japan
Last price 20.01 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 67.28B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 67.42B |
| Enterprise Value | 98.78B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 1.59B |
| Shares Change (YoY) | -1.27% |
| Shares Change (QoQ) | +0.99% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 50.69% |
| Float | 1.59B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 256.10 |
| Forward PE | 18.97 |
| PS Ratio | 2.26 |
| Forward PS | 2.24 |
| PB Ratio | 1.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.35 |
| P/OCF Ratio | 12.09 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 380.54 |
| EV / Sales | 3.31 |
| EV / EBITDA | 11.53 |
| EV / EBIT | 20.50 |
| EV / FCF | 22.49 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.15 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | 7.76 |
| Interest Coverage | 4.80 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 3.18% |
| Return on Invested Capital (ROIC) | 6.06% |
| Return on Capital Employed (ROCE) | 5.98% |
| Weighted Average Cost of Capital (WACC) | 3.97% |
| Revenue Per Employee | $635,023 |
| Profits Per Employee | $5,520 |
| Employee Count | 47,029 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 1.21 |
Taxes
| Measure | Value |
|---|
| Income Tax | -276.88M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +51.85% |
| 50-Day Moving Average | 18.84 |
| 200-Day Moving Average | 17.55 |
| Relative Strength Index (RSI) | 71.87 |
| Average Volume (20 Days) | 2,926,849 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.29M |
| Short Previous Month | 4.20M |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.21% |
| Short Ratio (days to cover) | 1.21 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 29.86B |
| Gross Profit | 19.34B |
| Operating Income | 4.82B |
| Pretax Income | -15.73M |
| Net Income | 259.59M |
| EBITDA | 8.57B |
| EBIT | 4.82B |
| Earnings Per Share (EPS) | $0.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.66B |
| Total Debt | 34.09B |
| Net Cash | -31.43B |
| Net Cash Per Share | -$19.72 |
| Equity (Book Value) | 47.20B |
| Book Value Per Share | 29.60 |
| Working Capital | 2.50B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 5.57B |
| Capital Expenditures | -1.18B |
| Depreciation & Amortization | 3.73B |
| Net Borrowing | -1.88B |
| Free Cash Flow | 4.39B |
| FCF Per Share | $2.76 |
Margins
| Measure | Value |
|---|
| Gross Margin | 64.77% |
| Operating Margin | 16.13% |
| Pretax Margin | -0.05% |
| Profit Margin | 0.87% |
| EBITDA Margin | 28.69% |
| EBIT Margin | 16.13% |
| FCF Margin | 14.77% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.49 |
| Dividend Yield | 2.36% |
| Dividend Growth (YoY) | -9.35% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 602.21% |
| FCF Payout Ratio | 17.84% |
| Buyback Yield | 1.27% |
| Shareholder Yield | 3.62% |
| Earnings Yield | 0.39% |
| FCF Yield | 6.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.08 |
| Price Target Difference | 10.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 3.12% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.21 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |